A NEW study published
in the Annals of Rheumatic
Diseases has demonstrated that
the glucosamine-chondroitin
combination conferred a benefit for
osteoarthritis patients.
The study was a double-blind
randomised placebo-controlled
clinical trial with two year follow up.
605 participants aged 45 to
75 years with chronic knee pain
and evidence of medial tibiofemoral
compartment narrowing
or joint space narrowing (JSN) were
included in the research.
Dosing was 1500 mg of
glucosamine sulfate and 800 mg of
chondroitin sulfate.
A statistically significant reduction
in JSN at two years was recorded
for the treated group supporting
previous studies with this
combination.
CLICK HERE to read the abstract.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jan 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jan 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.